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Tbjective: Current data suggest that erythropoietin protects the brain and the spinal
ord from ischemic and traumatic injury. In this study, we determined whether
rythropoietin protects the central nervous system during prolonged hypothermic
irculatory arrest in an experimental canine model.
ethods: Ten adult beagle dogs were randomly and intravenously injected with
ither 5000 U/kg recombinant human erythropoietin or normal saline. Each dog was
hen subjected to a cardiopulmonary bypass and 120 minutes of deep hypothermic
irculatory arrest (18°C). The level of tau proteins in the cerebrospinal fluid, a
odified marker of neurologic deficit in dogs, and the histopathologic characteris-
ics of the brains and spinal cords were then examined.
esults: The level of tau proteins was significantly lower in the erythropoietin-
reated group than in the untreated group at 6 hours (20  12 vs 144  54 pg/mL;
 .036) and 12 hours (64 35 vs 478 103 pg/mL; P .01) after the operation.
he total Neurologic Deficit Score was 59  31 (0, normal; 500, brain death) in the
rythropoietin-treated group, compared with 376  30 in the untreated group (P 
0117). Histopathologic examination revealed that ischemic neuronal changes and
poptosis in the hippocampus CA1 were significantly lower in the erythropoietin-
reated group (P  .01 and P  .028, respectively).
onclusions: This study showed that erythropoietin protected the central nervous
ystem during prolonged hypothermic circulatory arrest, partly by preventing both
ecrosis (ischemic neuronal changes) and apoptosis.
rythropoietin (EPO) is a glycoprotein that was first characterized as a kidney
cytokine that regulates hematopoiesis, or the production of blood cells. EPO
is also produced in the brain after oxidative or nitrosative stress.1,2
urrent data suggest that EPO protects the brain and spinal cord from ischemic and
raumatic injury.3,4 We hypothesized that EPO might extend the duration of safe
irculatory arrest. In this study, we determined whether EPO protects the central
ervous system during prolonged hypothermic circulatory arrest in an experimental
anine model.
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CSPaterials and Methods
nimal Care
his study was approved by the Animal Care and Use Committee
f the University of Tokyo. All animals were acclimatized in the
ection of Animal Research of the Center for Disease Biology and
ntegrative Medicine. All animals received humane care in com-
liance with the 1996 “Guide for the Care and Use of Laboratory
nimals” (Institute for Laboratory Animal Research).
xperimental Groups
en adult beagle dogs weighing 10 to 13 kg (mean, 11.5 kg) and
to 20 months of age (mean, 15.3 months) were randomly as-
igned to receive an intravenous injection of either EPO (ESPO;
poetin alpha genetic recombination; 5000 U/kg body weight;
harmaceutical Division of Kirin Brewery Co Ltd, Tokyo, Japan)
EPO group) or a saline placebo (control group) directly before
ndergoing a sternotomy.
xperimental Protocol
ll animals were premedicated with ketamine hydrochloride (10
g/kg intramuscularly), and anesthesia was induced and main-
ained with sodium pentobarbital throughout the operation. Sup-
ort with a pressure-controlled ventilator (Bird Mark-7 respirator;
ird Products Corporation, Viasys Healthcare Inc, Conshohocken,
a) was started on 100% oxygen after endotracheal intubation. A
artial laminectomy at the level of the first lumbar vertebra was
erformed, and a 20-gauge catheter was inserted into the external
pace containing cerebrospinal fluid (CSF) toward the cranial side
o allow continuous pressure monitoring of the CSF and sampling
t several time points. The femoral artery and the external jugular
ein were cannulated with 20-gauge catheters for blood sampling,
nd the arterial and central venous pressures were monitored
ontinuously. Blood samples were analyzed after correction for
ody temperature, pH, oxygen tension, carbon dioxide tension,
ase excess, carbonic acid, electrolytes, hemoglobin, and oxygen
aturation by using a blood gas analyzer (ABL505; Radiometer
edical Aps, Copenhagen, Denmark) and a hemoglobin and ox-
gen saturation analyzer (OMS2 Hemoximeter; Radiometer Med-
cal Aps). The core temperature was monitored in the esophagus
nd rectum.
ypothermic Circulatory Arrest Using
ardiopulmonary Bypass
efore systemic heparinization, 200 mL of blood was removed for
emodilutional autologous transfusion. A median sternotomy was
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
CSF  cerebrospinal fluid
EPO  erythropoietin
HDS  Histopathologic Damage Score
NDS  Neurologic Deficit Score
TUNEL deoxyuridine-5=-triphosphate biotin nick
end labelingerformed. After systemic heparinization (300 IU/kg), a 10F arte- f
332 The Journal of Thoracic and Cardiovascular Surgery ● Junial cannula (Medtronic Inc, Minneapolis, Minn) was inserted in
he ascending aorta, and a 36F venous single cannula (Terumo Co
td, Tokyo, Japan) was inserted in the right atrium. Extracorporeal
irculation was performed by using a membrane oxygenator (Ca-
iox RX-Baby RX; Terumo Co Ltd) and an extracorporeal pump
MHS-15-IV, MERA; Senko Medical Instrument Mfg Co Ltd,
okyo, Japan) containing a circuit primed with a hemodilute
olution of 400 mL of lactated Ringer solution, 50 mL of 20%
uman albumin, 20 mL of sodium bicarbonate, 100 mL of man-
itol, and 2500 IU of heparin. Cardiopulmonary bypass (CPB) was
stablished at a flow rate of 100 mL · kg1 · min1, and the flow
as adjusted to maintain a mixed venous oxygen saturation of
pproximately 75%. A 14-gauge catheter was inserted into the left
entricle from the apex to permit decompression of the left ven-
ricle during CPB. Animals were cooled to an esophageal temper-
ture of 18°C by using a heat exchanger. The pH was maintained
t 7.40 by means of pH-stat principles, with an arterial PCO2 of 35
o 40 mm Hg, corrected for body temperature. CPB with perfusion
ooling was performed for 45 minutes and was maintained for 10
inutes after reaching 18°C, before initiation of 120 minutes of
eep hypothermic circulatory arrest (DHCA). The core and viscera
emperatures were kept at 18°C by using ice packs and a cool room
emperature. Cardiac arrest was induced and maintained by con-
inuous infusion of cold cardioplegic solution after crossclamping
f the ascending aorta.
After DHCA, CPB was restarted. Cardioversion was per-
ABLE 1. Criteria for Neurologic Deficit Score
ariable Normal Weak Absent
entral nerve function
Light reflex 0 5 20
Lid reflex 0 5 20
Corneal reflex 0 5 20
Auditory reflex 0 5 20
Carinal reflex 0 5 20
espiration condition
Normal 0
Hyperventilation 25
Abnormal 50
Apnea 100
otor and sensory function
Movement of limbs 0 20 50
Motor response to pain 0 20 50
evel of consciousness
Normal 0
Cloudy 30
Delirium 45
Stupor 60
Coma 100
bnormality
No convulsion 0
Temporal convulsion 50
Serial recurrent convulsions 100
otal  sum of all sections
est possible total Neurologic Deficit Score, 0; worst possible, 500.ormed, if necessary, to resume the sinus rhythm at approximately
e 2006
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CS
P2°C, and mechanical ventilation was restarted. All animals were
hen slowly rewarmed to 37°C by using a heat exchanger and an
nfrared heater over 45 minutes and were slowly weaned from the
PB. After hemodynamic measurements, protamine was adminis-
ered, and the CPB was removed. Autologous blood (removed before
he operation) was then transfused. Finally, all wounds were closed;
he animals were kept connected to the ventilator throughout the entire
rocedure. The ventilator mode was gradually stepped down to con-
inuous positive airway pressure management to assess the animals’
espiratory conditions. Anesthesia was kept at a minimum to enable
he assessment of neurologic function until they awoke. At the mo-
ent of waking, they were anesthetized adequately again.
eurologic Assessment
postoperative neurologic assessment of each animal was per-
ormed by an independent observer who was a staff member of the
ection of Animal Research and was unaware of the experimental
roups. A modified Neurologic Deficit Score (NDS) in Dogs5-7
as used to evaluate the neurologic deficits. This measure evalu-
tes 5 general neurologic components (central nerve function,
espiration, motor and sensory function, level of consciousness,
nd behavior) on separate scales of 0 to 100. A total score of 500
ndicates the worst possible neurologic damage, whereas a score
f 0 is normal. All animals were closely evaluated for seizure
ctivity. We modified this scoring by changing the “behavior”
omponent to “abnormality” to enable the early postoperative
ondition of the animals to be evaluated (Table 1). A component
f motor and sensory function that included the function of the
ind limbs was used to assess the spinal cord.
erum EPO Levels
lood was sampled at several time points: before the operation,
uring CPB (rewarming), and 3, 6, and 12 hours after the opera-
ion. After centrifugation, the serum samples were stored at80°C
ntil analysis. Serum EPO concentrations were determined by
sing a commercially available radioimmunoassay kit (Riconbigen
PO kit; Mitsubishi Kagaku Iatron Inc, Tokyo, Japan).
SF Evaluation
SF was sampled at the same time points as the blood. The
ABLE 2. Continued
ariable Control Erythropoietin P value
emp—rectum (°C)
Preop 34.5 0.3 35.0 0.6 .3
CA 18.0 0.4 18.4 0.4 .60
Post 3h 32.7 0.3 32.8 0.3 .83
Post 6h 33.9 0.6 33.7 0.4 .75
Post 12h 34.6 0.4 34.2 0.5 .67
ata are mean  SEM. MAP, Mean arterial pressure; CSF, cerebrospinal
uid; PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial pres-
ure of carbon dioxide; SvO2, mixed venous saturation of oxygen; Temp,
emperature; Preop, preoperative; on CPB, on cardiopulmonary bypass;
ost 3h, 3 hours after operation; Post 6h, 6 hours after operation; Post 12h,
2 hours after operation; CA, circulatory arrest. *P  .05.ABLE 2. Physiologic variables
ariable Control Erythropoietin P value
ge (mo) 14.8  2.0 15.8  1.4 .83
ody weight (kg) 11.0 0.3 11.9  0.5 .30
ex (male/female
ratio)
3:2 3:2 .999
AP (mm Hg)
Preop 106.0  1.0 102.4  7.8 1.00
On CPB 56.0  3.0 59.6  5.4 .75
Post 3h 78.6  7.6 65.8  2.8 .14
Post 6h 82.2  9.7 76.2  4.2 .40
Post 12h 77.2  9.6 70.0  6.5 .75
SF pressure
(cm CSF)
Preop 11.4  0.6 12.4  0.7 .38
On CPB 11.2  1.2 11.8  0.9 .92
Post 3h 29.8  6.4 18.4  3.6 .21
Post 6h 34.0  16.8 17.4  3.1 .075
Post 12h 43.0  10.3 19.8  3.3 .045*
aO2 (mm Hg)
Preop 495.1  11.8 532.0  25.5 .30
On CPB 528.7 52.6 447.4  55.5 .21
Post 3h 685.5 30.6 628.4  93.7 .83
Post 6h 530.4 99.2 426.6  134.3 1.00
Post 12h 388.2 105.6 224.5  112.3 .30
aCO2
Preop 27.5  4.4 30.9  5.5 .53
On CPB 43.0  4.2 41.4  2.6 1.00
Post 3h 38.1  4.2 28.0  4.0 .10
Post 6h 35.6  3.6 33.0  3.8 .40
Post 12h 40.2  3.3 44.5  5.3 .53
rterial pH
Preop 7.44  0.06 7.43  0.05 1.00
On CPB 7.25  0.02 7.29  0.04 .67
Post 3h 7.29  0.06 7.35  0.05 .40
Post 6h 7.30  0.04 7.34  0.05 .46
Post 12h 7.23  0.02 7.20  0.03 .40
vO2 (%)
Preop 81.3  5.1 81.5  3.9 1.00
On CPB 99.5  0.2 99.3  0.6 .91
Post 3h 84.3  6.0 83.7  2.6 .40
Post 6h 68.2  5.6 67.8  8.1 1.00
Post 12h 40.8  4.0 48.3  8.7 .67
emoglobin
(g/dL)
Preop 12.5  0.7 13.1  1.1 .53
On CPB 5.4 0.3 5.8  0.3 .20
Post 3h 12.1  1.0 12.5  0.8 .68
Post 6h 11.3  1.5 11.1  1.7 1.00
Post 12h 10.3  1.6 9.8  1.8 1.00
emp—esophagus
(°C)
Preop 34.9  0.5 34.8  0.5 .92
CA 17.3  0.4 17.8  0.2 .40
Post 3h 32.8  0.5 32.4  0.4 .67
Post 6h 33.7  0.6 33.6  0.4 .75amples were centrifuged and stored at 80°C until analysis. The
and Cardiovascular Surgery ● Volume 131, Number 6 1333
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1
CSPau protein concentration, a marker of neuronal damage, was then
easured by using a commercially available enzyme-linked im-
unosorbent assay kit (Fino Scholar hTAU; Nipro, Osaka, Japan).
he EPO concentration of the CSF was also measured by using the
ethod described previously for the serum samples.
istopathologic Examination
t 12 hours after the operation, cardiac arrest was induced under
dequate anesthesia, and the brain and spinal cord were quickly
arvested. The entire brain and spinal cord were fixed with 7%
uffered formaldehyde solution. All coronal sections of the brain
nd all transverse sections of the spinal cord (5 mm thick) were
xamined for gross lesions, and the following sections were also
nvestigated: frontal lobe; parietal lobe; thalamus; hippocampus
A1; cerebellum; cervical cord, C3-4; thoracic cord, T9-10; and
umbar cord, L3-4. These sections were embedded in paraffin, cut
o a thickness of 10 m, stained with hematoxylin-eosin, and
xamined under a light microscope by a pathologist who was
naware of the experimental groups. During this early period after
he onset of hypoxic ischemic injury, the minimum criteria for the
iagnosis of ischemic neuronal damage included mild cytoplasmic
osinophilia, shrunken neurons with scalloping of the margins, and
uclear changes consisting of coarse nuclear chromatin or pykno-
is.8-11 A modified Histopathologic Damage Score (HDS)5 was
sed to evaluate the histopathologic damage. The score was de-
ned as follows: no damaged neurons (0), minimal (2), mild (4),
oderate (6), and severe (8).
etection of Apoptosis
he extent of apoptosis in the brain (hippocampus CA1 and
erebellum) and spinal cord (thoracic [T9-10] and lumbar [L3-4])
issue specimens was further examined by using a deoxyuridine-
=-triphosphate biotin nick end labeling (TUNEL) assay and the
igure 1. Postoperative Neurologic Deficit Scores. *P < .05. The
esults for each of the 5 components were as follows (P value
ndicates EPO group vs control group): A, central nerve function,
5  9.5 vs 90  4.2, P  .011; B, respiration condition, 0  0 vs
0  14, P  .0071; C, motor and sensory function, 16  7.5 vs
4  6.0, P  .0092; D, level of consciousness, 18  7.3 vs 63 
0, P  .010; E, abnormality, 10  10 vs 80  12, P  .015.eadEnd Colorimetric TUNEL System (Promega Corporation, t
334 The Journal of Thoracic and Cardiovascular Surgery ● Junadison, Wis). Paraffin-embedded specimens were sectioned at 3
o 4 m for use in the TUNEL assay. Positive controls (specimens
reated with deoxyribonuclease I) and negative controls (omission
f recombinant terminal deoxynucleotidyltransferase) were also
ncluded. By using this procedure, apoptotic nuclei were stained
ark brown with diaminobenzidine (TUNEL positive), and normal
uclei were counterstained blue-violet with hematoxylin (TUNEL
egative). Two operators who were unaware of the experimental
roups then counted the number of TUNEL-positive neurons in 3
eparate high-power fields (magnification, 200). The number of
poptotic neurons was scored on the basis of the percentage of the
otal number of neurons counted.1,2 The apoptotic score was
efined as follows: no TUNEL-positive neurons (0), less than 10%
2), 10% to 30% (4), 31% to 50% (6), and greater than 50% (8).
tatistical Analysis
ll data are presented as the mean  SEM. Comparisons between
he EPO and control groups were performed by using the nonpara-
etric Wilcoxon test. The Spearman rank order correlation coef-
cient was used to correlate the 12-hour postoperative NDS and
igure 2. A, Erythropoietin (EPO) levels in serum. B, EPO levels in
SF. preOp, before surgery; on CPB, on cardiopulmonary bypass;
ost 3h, 3 hours after operation; post 6h, 6 hours after operation;
ost 12h, 12 hours after operation. *P< .05. The serum EPO levels
U/L) were significantly higher in the EPO group than in the
ontrol group during CPB (15,390  3931 vs 5.8  0.5; P  .011)
nd at 3 hours (13,077  3930 vs 10.9  2.1; P  .012), 6 hours
9506  3482 vs 15.9  4.0; P  .012), and 12 hours (5496  2360
s 13.3  4.8; P  .012) after the operation. The EPO levels (U/L)
n the CSF were also significantly higher in the EPO group than in
he control group during CPB (176 21 vs 5.3 0.3; P .009) and
t 3 hours (3660  1637 vs 6.8  0.4; P  .011), 6 hours (1830 
178 vs 8.1 1.2; P .012), and 12 hours (1865 810 vs 8.9 1.6;
 .012) after the operation.au protein levels, as well as the NDS and HDS. All statistics were
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CS
Pomputed by using the JMP analysis program, version 5.1 (SAS
nstitute Inc, Cary, NC).
esults
hysiologic Variables
here were no significant differences in the preoperative
hysiologic variables between groups. During the postop-
rative period, the CSF pressure was significantly lower in
he EPO group at 12 hours after the operation (P  .045).
o other parameters were significantly different between
roups (Table 2). During this experimental period, no sig-
ificant differences in the preoperative, intraoperative, and
ostoperative hemoglobin concentrations were observed be-
ween groups.
eurologic Assessment
he final total NDS at 12 hours after the operation was
ignificantly lower in the EPO group (59  31) than in the
ontrol group (376  30; P  .012; Figure 1). Hind-limb
ovement in the EPO group was significantly better than in
he control group (P  .015): 2 dogs (40%) had weak
ind-limb movement, and 3 dogs (60%) had normal hind-
imb movement in the EPO group, whereas 1 dog (20%) had
eak hind-limb movement and 4 dogs (80%) had no hind-
imb movement in the control group.
erum EPO Levels
he serum EPO concentrations before the administration of
PO or saline were similar in the EPO and control groups
11.8  2.1 U/L vs 14.7  2.4 U/L; P  .68). After the
ystemic administration of EPO or saline, the serum EPO
evels were significantly higher in the EPO group than in the
igure 3. Tau protein levels in CSF. preOp, Preoperative; post 6h,
hours after operation; post 12h, 12 hours after operation. *P <
05. The tau protein levels (pg/mL) were significantly lower in the
PO group than in the control group at both 6 hours (20  12 vs
44  54; P  .036) and 12 hours (64  35 vs 478  103; P  .01)
fter the operation.ontrol group (Figure 2, A). g
The Journal of ThoracicPO Levels in the CSF
he EPO concentration in the CSF before the administration
f EPO or saline was similar in the EPO and control groups
8.2  0.7 U/L vs 7.3  0.6 U/L; P  .75). After the
ystemic administration of EPO or saline, the EPO levels in
he CSF were significantly higher in the EPO group than in
he control group (Figure 2, B).
au Protein Levels in the CSF
he tau protein concentrations in the CSF were measured
efore the operation and 6 and 12 hours after the operation.
o significant differences in the tau protein concentrations
efore the operation were seen between the EPO and control
roups (44.2 13.6 pg/mL vs 39.4 6.0 pg/mL; P  .60).
he tau protein levels were significantly lower in the EPO
igure 4. A, Histopathologic Damage Score (HDS). B, Apoptotic
core. FL, Frontal lobe; PL, parietal lobe; THA, thalamus; HIPCA1,
ippocampus CA1 area; CER, cerebellum; C, cervical cord; Th,
horacic cord; L, lumbar cord; TOTAL, total HDS. *P < .05. The
egional HDS values for the 8 anatomic areas were as follows:
rontal lobe (1.6  0.2 vs 3.2  0.5; P  .041), parietal lobe (1.2 
.4 vs 4.4  0.2; P  .01), thalamus (1.6  0.2 vs 4.8  0.5; P 
0097), hippocampus CA1 (1.4  0.2 vs 6.0  0.3; P  .0099),
erebellum (3.6  0.7 vs 7.0  0.4; P  .019), cervical cord (4.0 
.6 vs 6.4  0.7; P  .064), thoracic cord (3.2  0.8 vs 6.0  0.6;
 .049), and lumbar cord (4.8  0.5 vs 6.8  0.5; P  .041). The
poptotic scores in the hippocampus CA1 and cerebellum were
ignificantly lower in the EPO group than in the control group
2.8  0.5 vs 6.0  0.9 [P  .029] and 2.8  0.5 vs 6.0  0.6 [P 
017], respectively).roup than in the control group after the operation (Figure 3).
and Cardiovascular Surgery ● Volume 131, Number 6 1335
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1
CSPsignificant correlation between the 12-hour postoperative
otal NDS and tau protein levels was seen (Spearman cor-
elation coefficient [r]  0.7622; P  .011).
istopathologic Examination
o macroscopic gross lesions were observed in any of the
rain or spinal cord specimens. The total HDS was signif-
cantly lower in the EPO group than in the control group
21 2.6 vs 45 2.1; P .012). Regional HDS, except for
he cervical cord, showed similar significant group differ-
nces (Figure 4, A). A significant correlation between the
otal NDS and the HDS was observed (Spearman correla-
ion coefficient [r]  0.7669; P  .0096). Samples from
oth groups are shown in Figure 5, A-D.
etection of Apoptosis
he apoptotic scores in the hippocampus CA1 and cerebel-
um were significantly lower in the EPO group than in the
ontrol group. The differences in the apoptotic scores of the
pinal cord specimens were not significantly different be-
ween the 2 groups. However, the lumbar cord score tended
o be lower in the EPO group than in the control group
4.0  0 vs 5.2 0.5; P  .067; Figure 4, B). Samples from
he control group stained positive (dark brown with diami-
obenzidine) with numerous TUNEL-positive neurons scat-
ered in the hippocampus and cerebellum compared with
amples from the EPO group (Figure 5, E-H).
iscussion
PO is known mainly for its ability to stimulate the pro-
uction of red blood cells in bone marrow. EPO expression
s increased in the kidneys whenever low levels of oxy-
en occur, a condition sensed by the transcription factor
ypoxia-inducible factor 1. EPO is used to treat anemia in
atients with chronic renal failure.
EPO is also produced in the brain after oxidative stress.
oreover, neurons express receptors that detect EPO.1 Re-
ent studies have shown that EPO protects the brain and
pinal cord from ischemic injury by preventing apopto-
is.3,12-14 In this study, a TUNEL assay showed that EPO
an rescue neurons from apoptosis in selective vulnerability
reas,10,11 such as the hippocampus CA1 (Sommer sector)
nd the Purkinje cells of the cerebellum. Neurons in the
umbar cord also tend to be rescued by EPO. Apoptosis, or
rogrammed cell death, is a kind of delayed neuronal death
hat occurs 24 hours to 2 weeks after an insult.
This study revealed that EPO also significantly decreased
cute ischemic neuronal cell changes (microvacuolization, py-
notic nuclei, dense staining triangular nuclei, and shrunken
osinophilic cytoplasm). These findings suggest that EPO
ay also prevent necrosis, because acute ischemic neuronal
ell changes reflect early necrotic changes. We speculated
hat EPO may prevent brain edema caused by ischemic l
336 The Journal of Thoracic and Cardiovascular Surgery ● Juneuronal cell change (microvacuolization), thus leading to a
ower CSF pressure, because the CSF pressure has been
reviously shown to reflect the intracranial pressure.15 The
au proteins observed in our study were thought to be
roduced by ischemic damaged neurons. Brines and col-
igure 5. (A) and (B) are sections of the hippocampus CA1 area
stain, hematoxylin and eosin; original magnification, 200).
C) and (D) are sections of the cerebellum (stain, hematoxylin
nd eosin; original magnification, 200). (A) and (C) are from
he EPO group and show minimal evidence of cellular change.
B) and (D) are from the control group and show pyknotic
uclei, shrunken eosinophilic cytoplasm, and microvacuoliza-
ion. (D) also shows a decrease in the number of Purkinje
ells. TUNEL staining of sections of the hippocampus CA1 in
he EPO group (E) and the control group (F) and of the cere-
ellum in the EPO group (G) and the control group (H) is shown
original magnification, 200). (E) and (G) show minimal evi-
ence of TUNEL-positive neurons, whereas (F) and (H) exhibit
umerous scattered TUNEL-positive neurons (dark brown with
iaminobenzidine).eagues12 concluded that EPO could rescue neurons from
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Peath through not only the modulation of apoptosis, but also
he modulation of necrosis or immune-mediated injury. In
heir study, EPO was thought to play an acute neuroprotec-
ive role in apoptosis modulation by activating gene expres-
ion. Siren and colleagues3 also conjectured that EPO might
imit neuronal necrosis. Further experiments will be neces-
ary to determine the mechanism by which EPO prevents
ecrosis.
Romsi and associates16 showed the potential neuroprotec-
ive benefits of EPO during hypothermic circulatory arrest but
ailed to show any significant benefit in terms of mortality or
rain histopathology. The dose of EPO that they used (500
/kg of body weight) might have been inadequate. The dose
sed in this study (5000 U/kg of body weight) has also been
eported to have good neuroprotective effects in other arti-
les.3,17 Our data confirmed that intravenously administered
PO (a genetic recombination form) was able to cross the
lood-brain barrier during CPB and DHCA.
Although EPO’s ability to protect the central nervous sys-
em may be clinically useful, its erythropoietic activity would
e undesirable in patients with cardiovascular or cerebrovas-
ular diseases. Recent studies have shown that nonerythropoi-
tic variants of EPO (such as carbamylated EPO13 or asialo
PO14) may also provide tissue-protective effects.
If the dogs had been observed for a longer period of time,
uch as 1 week or more, a greater difference in functional
utcome might have been seen. However, the long-term
urvival of brain-damaged and laminectomized animals
ould be neither feasible nor humane. Therefore, we de-
ided to limit our postoperative observations to a 12-hour
eriod.
onclusion
his study showed that EPO protects the central nervous
ystem during prolonged hypothermic circulatory arrest,
artly by preventing both necrosis and apoptosis. This result
uggests that EPO may be useful for preventing neurologic
njury after aortic surgery.
We thank Mr Nobutaka Furuya and Mr Takashi Kubota for
heir technical assistance and Mr Masahiko Fujiwara (Koutou-
iken Institute of Pathology) for the TUNEL assay.
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